ACEA 1011
Latest Information Update: 30 Apr 1997
Price :
$50 *
At a glance
- Originator Purdue Pharma
- Class Anti-ischaemics; Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Neurological disorders
Most Recent Events
- 19 Dec 1996 New profile
- 19 Dec 1996 Discontinued-Preclinical for Epilepsy in USA (Unknown route)
- 19 Dec 1996 Discontinued-Preclinical for Neurological disorders in USA (Unknown route)